Actavis hit a hurdle for Alzheimer's blockbuster Namenda when a court nixed its plot to force patients over to a new, long-acting formula. But as the Dublin drugmaker waits for an answer from an appeals court, it's got a backup plan in place--one that's going very well, execs say.
Actavis said last month it stood to lose $200 million in sales if an appeals court didn't let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda before generics hit. But if it does? The Department of Health and Human Services (HHS) predicts it'll cost the federal government $6 billion at the least.
Actavis is rolling toward a Phase III trial with an eye treatment licensed from Switzerland's Molecular Partners, following through on a promise made in the lead-up to its $66 billion acquisition of Allergan.
Boston biotech Rhythm is advancing its lead drug into Phase IIb under the eye of Actavis, which has inked a deal to buy the gastrointestinal treatment if it likes what it sees.
With Actavis and Ironwood's first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) by clearly communicating the symptoms. Now that the team is back with its sophomore DTC effort, the goal is to encourage patients to find a solution to their problems. A branded, prescription solution.
Acadia Pharmaceuticals' shares rocketed up nearly 20% on Tuesday based on some news tied to two investor conferences. But the market wasn't reacting to anything the company said, instead reading into a pair of cancellations and deducing that a buyout might be in the offing.
Actavis announced FDA approval of its drug delivering intrauterine device, Liletta, as a form of reversible contraception.
Actavis won the FDA's blessing for a new combination antibiotic treatment targeting drug-resistant infections, setting the stage for a showdown with Merck and its $9.5 billion splash into the field.
Actavis, still awaiting the close of its $66 billion buyout of Allergan, is on the lookout for more bolt-on acquisitions.
The big series of acquisitions that is making Actavis--now changing its name to Allergan--into a top 10 Big Pharma company overnight also bequeathed the company with an oddly disjointed pipeline of would-be blockbusters. And the company rolled it all up for public viewing today for its investors, touting its potential for spurring $6 billion in new sales.